Cen is a shareholder in the Chinese pharmaceutical company Jiangsu Hengrui Medicine. The organisation creates hostility to cancer, against infective and pain reliever sedates, and had an income of 25.9 billion yuan in 2021. Additionally, he owns a stake in Hansoh Pharmaceutical Group, a Hong Kong-listed pharmaceutical company.

Cen Junda Career

Cen’s 17% stake in Jiangsu Hengrui Medicine, a Chinese manufacturer of anti-cancer medications, accounts for the majority of his wealth. The company’s report for the third quarter of 2022 indicates that he owns his stake through a holding company.

According to Hansoh Pharmaceutical Group’s 2022 semi-annual report, Cen also owns 15% of the company. Liu Xiaohan, the representative for the organisation, declined to remark on the extremely rich person’s total assets.

Cen Junda Facts

According to Hansoh Pharmaceutical Group’s prospectus for an initial public offering, his holding company Apex Medical was a founding shareholder in 2015. In June 2019, the company began trading on the Hong Kong stock exchange. The drug manufacturer’s chairwoman and Cen Huijuan are billionaires

Cen Junda Net Worth

Cen Junda’s net worth was estimated to be approximately $2 billion USD in 2023, according to Forbes’ Real-Time Billionaires List.

Personal Information

Also Read:

Natie Kirsh Net Worth, Age, Family & Biography

Victoria Mars Net Worth, Age, Family & Biography

Nancy Laurie Net Worth, Age, Family & Biography

The post Cen Junda<span class="post-spn"> Net Worth, Age, Family & Biography </span> <div class='sec-main'>$2.5 B Real Time Net Worth #329 in the world today</div> appeared first on Billionaire Index.